Running for a Cure: Laura and Gonzalo Take on Half Marathons for NF1

In January 2025, scientists-turned-entrepreneurs Laura Fletcher and Gonzalo Fernandez launched a UK-based biotech start-up with a bold mission: to develop a curative therapy for Neurofibromatosis Type 1 (NF1). Their company, CureAge Therapeutics, is the first of its kind — aiming to target the genetic root of NF1 and reshape how this complex condition is treated.

As a way of giving back to the community that has inspired and supported them throughout their journey, Laura and Gonzalo are lacing up their running shoes for a special fundraising effort in support of Nerve Tumours UK.

Laura will run her 21 km along the beautiful Welsh coast. Gonzalo will run his in sunny Barcelona.

“We wouldn’t be here without the support and trust of the NF community,” says Gonzalo. “This is our way of showing thanks and helping move one step closer to a cure.” Rather than joining an organised race, they’ve created their own routes — making it personal and meaningful.

CureAge is working to make curative treatments a reality for NF1. The name was chosen by patients and their families, representing the courage of the NF community and their hope for a cure. The company’s aim is to improve the lives of people with the condition by targeting it at its root. “Our work is driven by patients and their families” says Laura. “This run is a small way to honour that.”

You can support Laura and Gonzalo’s run by donating to Nerve Tumours UK. Every donation helps support families, raise awareness, and bring us closer to a cure.